Collagenase Santyl ointment is a selective enzymatic debriding agent that contains 250 collagenase units per gram of white petrolatum USP. The enzyme collagenase is derived from the fermentation of Clostridium histolyticum and possesses the ability to liquefy collagen in necrotic tissue without harming healthy granulation tissue.
Healthpoint has acquired the rights to market Collagenase Santyl ointment as part of its acquisition of the topical collagenase business from BioSpecifics Technologies in March 2006. Following transition of manufacturing operations, Healthpoint filed for and received authorization from Health Canada to re-introduce the product into the Canadian market.
Jay Nisbet, senior director of international business development at Healthpoint, said: “The reintroduction of Collagenase Santyl ointment is a strategic milestone for Healthpoint that reflects our commitment to supporting the brand in the Canadian market. We are particularly pleased that this portfolio extension also represents an important addition to the therapeutic landscape in Canada.”